IRVINE, Calif., June 4 /PRNewswire-FirstCall/ -- Endologix, Inc.
(Nasdaq: ELGX), developer of minimally invasive treatments for
aortic disorders, announced today that TechAmerica has named
Endologix as Orange County's
Outstanding Company in Medical Technology. The award was presented
to Endologix at the 17th Annual TechAmerica High-Tech Innovation
Awards on June 2, 2010 in
Irvine, CA.
John McDermott, President and
CEO, said, "It is an honor to receive this award from TechAmerica.
It is a testament to the hard work of all our employees and their
dedication to our mission to be the leading innovator of treatments
for aortic disorders. In the years ahead, we expect to introduce
additional new technologies that will further improve patient
outcomes and increase the adoption of our growing portfolio of
aortic devices."
About TechAmerica Orange County
TechAmerica is the largest resource for technology companies in
the United States and is the
industry's leading trade association. TechAmerica Orange County
serves the high-tech business interests of companies located in the
region by providing access to opportunities for networking,
business development, education and advocacy. Now in its 17th year,
the TechAmerica High-Tech Innovation Awards is a premier business
event that celebrates excellence and achievement in the region's
technology industry, and honors local companies, individuals and
products that drive innovation in Orange
County.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive
treatments for aortic disorders. The Company's flagship product is
the Powerlink® System, which is an endovascular stent graft for the
treatment of abdominal aortic aneurysms (AAA). AAA is a weakening
of the wall of the aorta, the largest artery in the body, resulting
in a balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it a leading cause of death in the U.S.
Additional information can be found on Endologix's Web site at
www.endologix.com.
Forward-Looking Statements
Except for historical information contained herein, this news
release contains forward-looking statements, the accuracy of which
are necessarily subject to risks and uncertainties, all of which
are difficult or impossible to predict accurately and many of which
are beyond the control of Endologix. Many factors may cause actual
results to differ materially from anticipated results, including
the success of sales efforts for the Powerlink System and related
new products, product research and development efforts, and other
economic, business, competitive and regulatory factors. The Company
undertakes no obligation to update its forward looking statements.
Please refer to the Company's Annual Report on Form 10-K for the
year ended December 31, 2009, and the
Company's other filings with the Securities and Exchange
Commission, for more detailed information regarding these risks and
other factors that may cause actual results to differ materially
from those expressed or implied.
|
|
|
|
|
COMPANY
CONTACT:
|
INVESTOR
CONTACTS:
|
|
Endologix, Inc.
|
The Ruth
Group
|
|
John McDermott, CEO
|
Nick Laudico (646)
536-7030
|
|
(949) 595-7200
|
Zack Kubow (646) 536-7020
|
|
www.endologix.com
|
|
|
|
|
|
|
SOURCE Endologix, Inc.